公开(公告)号：US20100197711A1

公开(公告)日：2010-08-05

申请号：US12678836

申请日：2007-09-27

申请人： Keith Geoffrey Watson ,  Guillaume Laurent Lessene ,  Jonathan Bayldon Baell ,  David Ching Siang Huang ,  Ian Philip Street ,  Jerry McKee Adams ,  Peter Malcolm Colman ,  Brad Edmund Sleebs ,  Brian John Smith ,  Peter Edward Czabotar

发明人： Keith Geoffrey Watson ,  Guillaume Laurent Lessene ,  Jonathan Bayldon Baell ,  David Ching Siang Huang ,  Ian Philip Street ,  Jerry McKee Adams ,  Peter Malcolm Colman ,  Brad Edmund Sleebs ,  Brian John Smith ,  Peter Edward Czabotar

IPC分类号： A61K31/428 ,  C07D277/82 ,  C07D417/12 ,  C12N5/09 ,  A61K31/506 ,  A61K31/4439 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P35/02 ,  A61P19/02

CPC分类号： C07D417/12 ,  C07D277/82 ,  C07D417/14

摘要： The present invention relates to benzothiazole compounds that mimic the activity of BH3 only proteins and are capable of binding to and neutralizing pro survival Bcl 2 proteins. The invention also relates to the use of such compounds in the regulation of cell death or cell survival and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death or cell survival.

摘要翻译： 本发明涉及苯并噻唑化合物，其类似于仅BH3蛋白的活性并且能够结合和中和生存的Bcl 2蛋白。 本发明还涉及这些化合物在调节细胞死亡或细胞存活以及治疗和/或预防与细胞死亡或细胞存活失调相关的疾病或病症中的用途。

公开(公告)号：US20100190782A1

公开(公告)日：2010-07-29

申请号：US12641063

申请日：2009-12-17

申请人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Carl Steven Rye ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Andrew M. Petros ,  Andrew J. Souers

发明人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Carl Steven Rye ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Andrew M. Petros ,  Andrew J. Souers

IPC分类号： A61K31/536 ,  C07D417/14 ,  A61K31/4709 ,  C07D487/04 ,  A61K31/519 ,  A61K31/502 ,  A61K31/428 ,  A61K31/5377 ,  A61P35/02 ,  A61P35/00 ,  A61P7/02 ,  A61P9/00

CPC分类号： C07D417/14 ,  C07D417/12 ,  C07D487/04

摘要： In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

摘要翻译： 一方面，本发明提供式I化合物，其中在式I中，变量X1，X2a，X2b，X2c，R1，B，L，E，A和下标n如本文所定义。 另一方面，本发明提供包含式I化合物的药物组合物以及使用式I化合物治疗以表达或过表达为特征的疾病和病症（例如，癌症，血小板增多症等）的方法 的Bcl-2抗凋亡蛋白，例如抗凋亡Bcl-xL蛋白。

公开(公告)号：US20120184541A1

公开(公告)日：2012-07-19

申请号：US13347364

申请日：2012-01-10

申请人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Carl Steven Rye ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Andrew M. Petros ,  Andrew J. Souers ,  Peter Czabotar

发明人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Carl Steven Rye ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Andrew M. Petros ,  Andrew J. Souers ,  Peter Czabotar

IPC分类号： A61K31/4709 ,  A61K31/519 ,  A61P9/00 ,  A61P35/00 ,  A61P35/02 ,  A61P7/02 ,  A61K31/538 ,  A61K31/498

CPC分类号： C07D417/14 ,  C07D417/12 ,  C07D487/04

摘要： In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

摘要翻译： 一方面，本发明提供式I化合物，其中在式I中，变量X1，X2a，X2b，X2c，R1，B，L，E，A和下标n如本文所定义。 另一方面，本发明提供包含式I化合物的药物组合物以及使用式I化合物治疗以表达或过表达为特征的疾病和病症（例如，癌症，血小板增多症等）的方法 的Bcl-2抗凋亡蛋白，例如抗凋亡Bcl-xL蛋白。

公开(公告)号：US08232273B2

公开(公告)日：2012-07-31

申请号：US12641141

申请日：2009-12-17

申请人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Peter Czabotar ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Lisa A. Hasvold ,  Andrew M. Petros ,  Andrew J. Souers ,  Zhi-Fu Tao ,  Le Wang ,  Xilu Wang ,  Kurt Deshayes

发明人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Peter Czabotar ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Lisa A. Hasvold ,  Andrew M. Petros ,  Andrew J. Souers ,  Zhi-Fu Tao ,  Le Wang ,  Xilu Wang ,  Kurt Deshayes

IPC分类号： A61K31/5377 ,  C07D413/14

CPC分类号： C07D417/14 ,  C07D471/06 ,  C07D473/00 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  C07D513/06

摘要： In one aspect, the present invention provides for a compound of Formula I in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

摘要翻译： 一方面，本发明提供了其中变量X1a，X1b，X1c，X1d，Q，A，R1，B，L，E和下标m和n具有如本文所述的含义的式I化合物 。 另一方面，本发明提供包含式I化合物的药物组合物以及使用式I化合物治疗以表达或过表达为特征的疾病和病症（例如，癌症，血小板增多症等）的方法 的Bcl-2抗凋亡蛋白，例如抗凋亡Bcl-xL蛋白。

公开(公告)号：US08114893B2

公开(公告)日：2012-02-14

申请号：US12641063

申请日：2009-12-17

申请人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Carl Steven Rye ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Andrew M. Petros ,  Andrew J. Souers ,  Peter Czabotar

发明人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Carl Steven Rye ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Andrew M. Petros ,  Andrew J. Souers ,  Peter Czabotar

IPC分类号： C07D417/14 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/496 ,  A61K31/498 ,  A61K31/4709

CPC分类号： C07D417/14 ,  C07D417/12 ,  C07D487/04

摘要： In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

摘要翻译： 一方面，本发明提供式I化合物，其中在式I中，变量X1，X2a，X2b，X2c，R1，B，L，E，A和下标n如本文所定义。 另一方面，本发明提供包含式I化合物的药物组合物以及使用式I化合物治疗以表达或过表达为特征的疾病和病症（例如，癌症，血小板增多症等）的方法 的Bcl-2抗凋亡蛋白，例如抗凋亡Bcl-xL蛋白。

公开(公告)号：US08518970B2

公开(公告)日：2013-08-27

申请号：US13347364

申请日：2012-01-10

申请人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Carl Steven Rye ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Andrew M. Petros ,  Andrew J. Souers ,  Peter Czabotar

发明人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A. Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Carl Steven Rye ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Andrew M. Petros ,  Andrew J. Souers ,  Peter Czabotar

IPC分类号： C07D417/14 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/496 ,  A61K31/498 ,  A61K31/4709

CPC分类号： C07D417/14 ,  C07D417/12 ,  C07D487/04

摘要： In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

公开(公告)号：US20100210622A1

公开(公告)日：2010-08-19

申请号：US12641141

申请日：2009-12-17

申请人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Peter Czabotar ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A, Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Lisa A. Hasvold ,  Andrew M. Petros ,  Andrew J. Souers ,  Zhi-Fu Tao ,  Le Wang ,  Xilu Wang ,  Kurt Deshayes

发明人： Jonathan Bayldon Baell ,  Chinh Thien Bui ,  Peter Colman ,  Peter Czabotar ,  Danette A. Dudley ,  Wayne J. Fairbrother ,  John A, Flygare ,  Guillaume Laurent Lessene ,  Chudi Ndubaku ,  George Nikolakopoulos ,  Brad Edmund Sleebs ,  Brian John Smith ,  Keith Geoffrey Watson ,  Steven W. Elmore ,  Lisa A. Hasvold ,  Andrew M. Petros ,  Andrew J. Souers ,  Zhi-Fu Tao ,  Le Wang ,  Xilu Wang ,  Kurt Deshayes

IPC分类号： A61K31/4725 ,  C07D417/14 ,  A61P35/02 ,  A61P35/00 ,  A61P9/00 ,  A61P7/02 ,  C07D471/04 ,  A61K31/5377 ,  C07D487/04 ,  A61K31/519 ,  A61K31/496 ,  C07D471/06 ,  A61K31/4745

CPC分类号： C07D417/14 ,  C07D471/06 ,  C07D473/00 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  C07D513/06

摘要： In one aspect, the present invention provides for a compound of Formula I in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

摘要翻译： 一方面，本发明提供了其中变量X1a，X1b，X1c，X1d，Q，A，R1，B，L，E和下标m和n具有如本文所述的含义的式I化合物 。 另一方面，本发明提供包含式I化合物的药物组合物以及使用式I化合物治疗以表达或过表达为特征的疾病和病症（例如，癌症，血小板增多症等）的方法 的Bcl-2抗凋亡蛋白，例如抗凋亡Bcl-xL蛋白。

公开(公告)号：US20120122771A1

公开(公告)日：2012-05-17

申请号：US13265879

申请日：2010-03-09

申请人： Michael Colin Lawrence ,  Brian John Smith ,  John Gerbrandt Tasman Menting ,  Colin Wesley Ward

发明人： Michael Colin Lawrence ,  Brian John Smith ,  John Gerbrandt Tasman Menting ,  Colin Wesley Ward

IPC分类号： A61K38/10 ,  C07K1/107 ,  C07K7/08 ,  C12N15/12 ,  G06F19/00 ,  A61P3/10 ,  A61P9/10 ,  A61P19/10 ,  A61P35/00 ,  A61P25/28 ,  G01N33/53 ,  A61P3/04

CPC分类号： G06F19/12 ,  C07K14/72 ,  G01N33/566

摘要： The present invention relates generally to structural studies of the insulin binding site of the insulin receptor (IR) and the insulin-like growth factor 1 receptor (IGF-1R). More particularly, the present invention relates to the crystal structure of the low affinity insulin binding site of the IR ectodomain comprising the C-terminal region of the IR α-chain, as well as the corresponding region of IGF-1R, and to methods of using the crystal and related structural information to screen for and design compounds that interact with or modulate the function of IR and/or IGF-1R.

摘要翻译： 本发明一般涉及胰岛素受体（IR）和胰岛素样生长因子1受体（IGF-1R）的胰岛素结合位点的结构研究。 更具体地，本发明涉及包含IRα链的C末端区域以及IGF-1R的相应区域的IR胞外域的低亲和力胰岛素结合位点的晶体结构，以及 使用晶体和相关的结构信息来筛选和设计与IR和/或IGF-1R的功能相互作用或调节其功能的化合物。

公开(公告)号：US20110276296A1

公开(公告)日：2011-11-10

申请号：US13123497

申请日：2009-10-12

申请人： Ian Alexander Walmsley ,  Brian John Smith ,  Jeffrey Stephen Lundeen ,  Peter James Mosley ,  Graciana Puentes ,  Hendrik Bernd Coldenstrodt-Ronge ,  Nicholas Lloyd Thomas-Peter ,  Andrew Philip Worsley

发明人： Ian Alexander Walmsley ,  Brian John Smith ,  Jeffrey Stephen Lundeen ,  Peter James Mosley ,  Graciana Puentes ,  Hendrik Bernd Coldenstrodt-Ronge ,  Nicholas Lloyd Thomas-Peter ,  Andrew Philip Worsley

IPC分类号： G06F19/00

CPC分类号： G01J11/00

摘要： A method of calibrating an optical detector arrangement (38,42) comprises simultaneously generating a plurality of entangled photon pairs, such that one photon from each pair traverses a first path (36-38-42) and the other photon from each pair traverses a second path (36-40-44). The number of photons received along the first path is calculated using the detector arrangement (38,42), while the number of simultaneously-generated photons received along the second path is calculated using a second detector arrangement (40,44). These photon numbers are used to calculated an estimate of the detection efficiency (50) of the first detector arrangement (38,42).

摘要翻译： 校准光学检测器装置（38,42）的方法包括同时产生多个纠缠的光子对，使得每一对的一个光子穿过第一路径（36-38-42），并且来自每一对的另一个光子穿过一个 第二路（36-40-44）。 使用检测器装置（38,42）计算沿着第一路径接收的光子的数量，而使用第二检测器装置（40,44）计算沿着第二路径接收的同时生成的光子的数量。 这些光子数用于计算第一检测器装置（38,42）的检测效率（50）的估计。

公开(公告)号：US20110068195A1

公开(公告)日：2011-03-24

申请号：US12923293

申请日：2010-09-14

申请人： Kevin Michael Franks ,  Donnie Russell Fisher ,  Brian John Smith

发明人： Kevin Michael Franks ,  Donnie Russell Fisher ,  Brian John Smith

IPC分类号： B05B15/08

CPC分类号： B05B15/70 ,  B05B1/3006 ,  B05B15/40 ,  B05B15/74

摘要： A sprinkler for producing a fixed spray pattern includes an inner flow conduit having a nozzle at an outlet. A filter screen is held in place beneath the nozzle. The filter screen engages a push rod of a valve of a flow stop mechanism. The push rod spaces a valve member away from a valve seat to permit water flow through the inner flow conduit when the filter screen and nozzle are in place. If the nozzle is removed or if the inner conduit is severed, the filter screen can be removed, which causes the valve member to close under the force of water pressure and to shut off flow through the inner flow conduit. The valve is located upstream of parts that are vulnerable to damage.

摘要翻译： 用于生产固定喷雾图案的喷洒器包括在出口处具有喷嘴的内部流动管道。 过滤网被保持在喷嘴下方。 过滤网与流动停止机构的阀的推杆接合。 当过滤网和喷嘴就位时，推杆使阀构件远离阀座使空气流过内流道。 如果喷嘴被去除或者内部管道被切断，则可以去除过滤网，这导致阀构件在水压力作用下关闭，并且阻止流过内部流动管道。 阀门位于容易受到损坏的部件的上游。